Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoCHGCF -2.45%85 3-Year EBITDA Growth Rate is 4.00% as of Jun. 2026, which is 44% below its 10-year median of 7.15. GuruFocus rates CHGCF with a GF Scoreâ„¢ of 85/100 and a GF Valueâ„¢ of $47.62 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 809 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 59.46% on this metric.
During the past 12 months, Chugai Pharmaceutical Co's average EBITDA Per Share Growth Rate was 17.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 26.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chugai Pharmaceutical Co was 51.10% per year. The lowest was -12.60% per year. And the median was 7.15% per year.
Chugai Pharmaceutical Co (OTCPK:CHGCF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Chugai Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms
CHGCF vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.
Chugai Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.00% mean?
Chugai Pharmaceutical Co (CHGCF) has a 3-Year EBITDA Growth Rate of 4.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chugai Pharmaceutical Co and its competitors. This is 44% below median its historical median of 7.15. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #481 out of 809 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Chugai Pharmaceutical Co's 3-Year EBITDA Growth Rate too high?
Chugai Pharmaceutical Co's current 3-Year EBITDA Growth Rate of 4.00% is 44% below median its 10-year median of 7.15. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Chugai Pharmaceutical Co's value of 4.00% is 55.1% below this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #481 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Scoreâ„¢ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #481 out of 809 companies for 3-Year EBITDA Growth Rate. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Chugai Pharmaceutical Co's value of 4.00% is 55.1% below this benchmark. While the company's 10-year median is 7.15 vs. the industry median of 8.90, Chugai Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current 3-Year EBITDA Growth Rate of 4.00% is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current 3-Year EBITDA Growth Rate is 4.00%, which is 44% below median its own 10-year median of 7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.62, compared to a current price of $42.03 — trading 11.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.00%, which is 44% below median its 10-year median of 7.15 and 55.1% below the Drug Manufacturers industry median of 8.90. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current 3-Year EBITDA Growth Rate is 4.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $42.03 is trading 11.7% below its estimated GF Value™ of $47.62.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for CHGCF:
3-Year EBITDA Growth Rate: 4.00% (44% below median its 10-year median of 7.15)
GF Value™: $47.62 vs. price of $42.03 (11.7% below fair value)
Industry Position: 55.1% below the Drug Manufacturers median (#481 of 809)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score
Get the complete analysis for CHGCF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
